RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS

      Optimization of the experimental conditions for determination of roxithromycin in bulk and dosage forms

      한글로보기

      https://www.riss.kr/link?id=A104828703

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Roxithromycin (RXT), which is an antibiotic used to treat respiratory tract and urinary infections, is official in Korean Pharmacopoeia (KP) and is marketed in various dosage forms including tablet, granule, suspension, and tablet for suspension in Korea. This study presents how a universal and reliable method to quantify RXT in bulk drug and formulations was developed. Effects of factors including column type, buffer concentration, type and concentration of organic solvent, buffer pH, and type and concentration of mobile phase additive, were examined, and some categorical or crucial factors including the types of column, organic solvent, mobile phase additive and the buffer pH were optimized by one-factor-at-a-time approach. Subsequently, concentrations of the buffer and additive and column temperature were optimized by response surface methodology using Box-Behnken design aiming to acquire the RXT peak of good shape. The optimized method employed a Phenomenex Gemini 5μ C18 110A (150 × 4.60 mm, 5 μm) maintained at 30 °C with the mobile phase consisting of 25 mM phosphate buffer (pH 6.0) with 0.3 % tetrabutylammonium hydroxide and methanol at a ratio of 37:63 (v/v). Method validation results showed that the developed method was linear, precise, and accurate. Compared to the compendial methods in KP 10 that exhibited a significant tailing of the RXT peak despite using unfavorably high buffer concentrations and were not harmonized among bulk drug and formulations, this method could be universally applied to RXT bulk drug and marketed products in various dosage forms and thus was adopted in KP 11.
      번역하기

      Roxithromycin (RXT), which is an antibiotic used to treat respiratory tract and urinary infections, is official in Korean Pharmacopoeia (KP) and is marketed in various dosage forms including tablet, granule, suspension, and tablet for suspension in Ko...

      Roxithromycin (RXT), which is an antibiotic used to treat respiratory tract and urinary infections, is official in Korean Pharmacopoeia (KP) and is marketed in various dosage forms including tablet, granule, suspension, and tablet for suspension in Korea. This study presents how a universal and reliable method to quantify RXT in bulk drug and formulations was developed. Effects of factors including column type, buffer concentration, type and concentration of organic solvent, buffer pH, and type and concentration of mobile phase additive, were examined, and some categorical or crucial factors including the types of column, organic solvent, mobile phase additive and the buffer pH were optimized by one-factor-at-a-time approach. Subsequently, concentrations of the buffer and additive and column temperature were optimized by response surface methodology using Box-Behnken design aiming to acquire the RXT peak of good shape. The optimized method employed a Phenomenex Gemini 5μ C18 110A (150 × 4.60 mm, 5 μm) maintained at 30 °C with the mobile phase consisting of 25 mM phosphate buffer (pH 6.0) with 0.3 % tetrabutylammonium hydroxide and methanol at a ratio of 37:63 (v/v). Method validation results showed that the developed method was linear, precise, and accurate. Compared to the compendial methods in KP 10 that exhibited a significant tailing of the RXT peak despite using unfavorably high buffer concentrations and were not harmonized among bulk drug and formulations, this method could be universally applied to RXT bulk drug and marketed products in various dosage forms and thus was adopted in KP 11.

      더보기

      참고문헌 (Reference)

      1 D. G. Kennedy, 812 (812): 77-98, 1998

      2 A. Pappa-Louisi, 755 (755): 57-64, 2001

      3 J. Macek, 723 (723): 233-238, 1999

      4 S. Şanli, 66 (66): 838-, 2011

      5 J. Macek, 723 (723): 233-238, 1999

      6 M. Wahba, 51 (51): 44-52, 2013

      7 H. Chepkwony, 54 (54): 725-729, 2001

      8 V. de Oliveira, 29 (29): 2377-2382, 1996

      9 J. S. Torano, 720 (720): 89-97, 1998

      10 C. Taninaka, 738 (738): 405-411, 2000

      1 D. G. Kennedy, 812 (812): 77-98, 1998

      2 A. Pappa-Louisi, 755 (755): 57-64, 2001

      3 J. Macek, 723 (723): 233-238, 1999

      4 S. Şanli, 66 (66): 838-, 2011

      5 J. Macek, 723 (723): 233-238, 1999

      6 M. Wahba, 51 (51): 44-52, 2013

      7 H. Chepkwony, 54 (54): 725-729, 2001

      8 V. de Oliveira, 29 (29): 2377-2382, 1996

      9 J. S. Torano, 720 (720): 89-97, 1998

      10 C. Taninaka, 738 (738): 405-411, 2000

      11 N. Grgurinovich, 433 : 298-304, 1988

      12 J. -H. Lim, 746 (746): 219-225, 2000

      13 P. Wang, 39 (39): 618-623, 2005

      14 정경민, "Highly efficient extraction of anthocyanins from grape skin using deep eutectic solvents as green and tunable media" 대한약학회 38 (38): 2143-2152, 2015

      15 P. S. B. Drug Evaluation Department, "Guideline of Validation of Analytical Procedures for Pharmaceuticals’"

      16 "A. D. Russell"

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2016-01-01 평가 등재학술지 선정 (계속평가) KCI등재
      2015-12-01 평가 등재후보로 하락 (기타) KCI등재후보
      2011-02-28 학술지명변경 외국어명 : Analytuacl Science & Technology -> Analytical Science & Technology KCI등재
      2011-01-01 평가 등재 1차 FAIL (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2004-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2003-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 유지 (등재후보1차) KCI등재후보
      2000-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.24 0.24 0.2
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.22 0.2 0.393 0.05
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼